Tag
First person treated in a gene therapy trial using partial reprogramming to rejuvenate cells, aiming to treat glaucoma by regenerating optic nerve neurons.
This newsletter covers David Sinclair's plan to test whole-body rejuvenation drugs in the XPrize competition, key AI trends from a talk at SXSW London, and OpenAI's confidential IPO filing.
David Sinclair plans to test an oral epigenetic reprogramming drug, SL-100, in the XPrize competition for whole-body rejuvenation, aiming for a 10-year age reversal.